Increased vancomycin minimum inhibitory concentration among Staphylococcus aureus isolates in Malaysia

References

1. CLSI 2006 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically ; Approved Standard, 7th edn. M7-A7, vol. 26 no. 2 Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
2. CLSI 2009 Performance Standards for Antimicrobial Susceptibility Testing ; 19th Informational Supplement M100-S19, vol. 29 no. 3 Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
3. Hidayat L. K., Hsu D. I., Quist R., Shriner K. A., Wong-Beringer A. 2006; High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138–2144 [CrossRef]
   [Google Scholar]
4. Ho P. L., Lo P. Y., Chow K. H., Lau E. H., Lai E. L., Cheng V. C., Kao R. Y. 2010; Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect 60:140–145 [CrossRef]
   [Google Scholar]
5. Hsu D. I., Hidayat L. K., Quist R., Hindler J., Karslsson A., Yusof A., Wong-Beringer A. 2008; Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 32:378–385 [CrossRef]
   [Google Scholar]
6. Liu C., Chambers H. F. 2003; Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 47:3040–3045 [CrossRef]
   [Google Scholar]
7. Lodise T. P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B. M., Stellrecht K. 2008; Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteraemia treated with vancomycin. Antimicrob Agents Chemother 52:3315–3320 [CrossRef]
   [Google Scholar]
8. Ministry of Health 2008 National Surveillance of Antibiotic Resistance Report Malaysia: Ministry of Health; http://www.imr.gov.my/report/nsar.htm
   [Google Scholar]
9. Moise P. A., Schentag J. J. 2000; Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 16:S31–S34
   [Google Scholar]
10. Moise P. A., Smyth D. A., El-Fawal N., Robinson D. A., Holden P. N., Forrest A., Sakoulas G. 2008; Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 61:85–90
    [Google Scholar]
11. Norazah A., Salbiah N., Nurizzat M., Santhana R. 2009; Vancomycin treatment failure in a vancomycin susceptible methicillin-resistant Staphylococcus aureus (MRSA) infected patient. Med J Malaysia 64:166–167
    [Google Scholar]
12. Prakash V., Lewis J. S., Jorgensen J. H. 2008; Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 52:4528 [CrossRef]
    [Google Scholar]
13. Robert J., Bismuth R., Jarlier V. 2006; Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus : a 20 year study in a large French teaching hospital, 1983–2002. J Antimicrob Chemother 57:506–510 [CrossRef]
    [Google Scholar]
14. Sader H. S., Rhomberg P. R., Jones R. N. 2009; Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 53:3162–3165 [CrossRef]
    [Google Scholar]
15. Sakoulas G., Moise-Broder P. A., Schentag J., Forest A., Moellering R. C., Eliopoulos G. M. 2004; Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Microbiol 42:2398–2402 [CrossRef]
    [Google Scholar]
16. Soriano A., Marco F., Martinez J. A., Pisos E., Almela M., Dimova V. P., Alamo D., Ortega M., Lopez J., Mensa J. 2008; Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin Infect Dis 46:193–200 [CrossRef]
    [Google Scholar]
17. Steinkraus G., White R., Friedrich L. 2007; Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother 60:788–794 [CrossRef]
    [Google Scholar]
18. Walsh T. R., Bolmström A., Qwärnström A., Ho P., Wootton M., Howe R. A., MacGowan A. P., Diekema D. 2001; Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39:2439–2444 [CrossRef]
    [Google Scholar]
19. Wang G., Hindler J. F., Ward K. W., Bruckner D. A. 2006; Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44:3883–3886 [CrossRef]
    [Google Scholar]